The Effect of Medical Cannabis Dispensaries on Opioid and Heroin Overdose Mortality

Garin, Julio and Pohl, R. Vincent and Smith, Rhet A. (2018): The Effect of Medical Cannabis Dispensaries on Opioid and Heroin Overdose Mortality.

Abstract

Opioid overdose is the most common cause of accidental death in the United States and no policy response has been able to contain this epidemic to date. We examine whether local access to medical cannabis can reduce opioid-related mortality. Using a unique data set of medical cannabis dispensaries combined with county-level mortality data, we estimate the effect of dispensaries operating in a county on the number of overdose deaths. We find that counties with dispensaries experience 6% to 8% fewer opioid-related deaths among non-Hispanic white men. Mortality involving heroin declines by approximately 10% following the opening of a dispensary.

• Item Type: MPRA Paper
• Language: English
• Keywords: Cannabis Dispensaries; Medical Cannabis Laws; Marijuana; Opioid Overdoses; Heroin Overdoses; Opioid Epidemic
• Subjects: I - Health, Education, and Welfare > I1 - Health > I12 - Health Behavior; I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health; K - Law and Economics > K3 - Other Substantive Areas of Law > K32 - Environmental, Health, and Safety Law

References

Bachhuber, Marcus A., Brendan Saloner, Chinazo O. Cunningham, and Colleen L. Barry. 2014. “Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010.” JAMA Internal Medicine 174 (10):1668–1673.

Bradford, Ashley C. and W. David Bradford. 2016. “Medical Marijuana Laws Reduce Pre- scription Medication Use In Medicare Part D.” Health Affairs 35 (7):1230–1236.

———. 2017. “Medical Marijuana Laws May Be Associated With A Decline In The Number Of Prescriptions For Medicaid Enrollees.” Health Affairs 36 (5):945–951.

Bradford, Ashley C., W. David Bradford, Amanda Abraham, and Grace Bagwell Adams. 2018. “Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population.” JAMA Internal Medicine 178 (5):667–672.

Buchmueller, Thomas C. and Colleen Carey. 2018. “The Effect of Prescription Drug Monitor- ing Programs on Opioid Utilization in Medicare.” American Economic Journal: Economic Policy 10 (1):77–112.

Cameron, A. Colin and Pravin K. Trivedi. 2005. Microeconometrics. Methods and Applica- tions. New York: Cambridge University Press.

Case, Anne and Angus Deaton. 2015. “Rising Morbidity and Mortality in Midlife among White Non-Hispanic Americans in the 21st Century.” Proceedings of the National Academy of Sciences 112 (49):15078–15083.

Chu, Yu-Wei Luke. 2015. “Do Medical Marijuana Laws Increase Hard-Drug Use?” The Journal of Law and Economics 58 (2):481–517.

Compton, Wilson M., Christopher M. Jones, and Grant T. Baldwin. 2016. “Relationship between Nonmedical Prescription-Opioid Use and Heroin Use.” New England Journal of Medicine 374 (2):154–163.

Dave, Dhaval M., Anca M. Grecu, and Henry Saffer. 2017. “Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse.” NBER Working Paper 23537.

Doleac, Jennifer L. and Anita Mukherjee. 2018. “The Moral Hazard of Lifesaving Inno- vations: Naloxone Access, Opioid Abuse, and Crime.” https://ssrn.com/abstract= 3135264.

Fergusson, David M., Joseph M. Boden, and L. Horwood. 2006. “Testing the Cannabis Gateway Hypothesis: Replies to Hall, Kandel et Al. and MacCoun (2006).” Addiction 101 (4):474–476.

Finney, John W., Keith Humphreys, and Alex H.S. Harris. 2015. “What Ecologic Analy- ses Cannot Tell Us about Medical Marijuana Legalization and Opioid Pain Medication Mortality.” JAMA Internal Medicine 175 (4):655–656.

Hall, Wayne and Michael Lynskey. 2005. “Is Cannabis a Gateway Drug? Testing Hypotheses about the Relationship between Cannabis Use and the Use of Other Illicit Drugs.” Drug and Alcohol Review 24 (1):39–48.

Hall, Wayne, Robert West, John Marsden, Keith Humphreys, Jo Neale, and Nancy Petry. 2018. “It Is Premature to Expand Access to Medicinal Cannabis in Hopes of Solving the US Opioid Crisis.” Addiction 113 (6):987–988.

Hurd, Yasmin L. 2017. “Cannabidiol: Swinging the Marijuana Pendulum From Weed to Medication to Treat the Opioid Epidemic.” Trends in Neurosciences 40 (3):124–127.

Hurd, Yasmin L., Michelle Yoon, Alex F. Manini, Stephanie Hernandez, Ruben Olmedo, Maria Ostman, and Didier Jutras-Aswad. 2015. “Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage.” Neurotherapeutics 12 (4):807–815.

Kandel, Denise. 1975. “Stages in Adolescent Involvement in Drug Use.” Science 190 (4217):912–914.

Li, Guohua, Joanne E. Brady, Barbara H. Lang, James Giglio, Hannah Wunsch, and Charles DiMaggio. 2014. “Prescription Drug Monitoring and Drug Overdose Mortality.” Injury Epidemiology 1 (9):1–8.

Meinhofer, Anglica. 2017. “Prescription Drug Monitoring Programs: The Role of Asymmet- ric Information on Drug Availability and Abuse.” American Journal of Health Economics online first.

Morral, Andrew R., Daniel F. McCaffrey, and Susan M. Paddock. 2002. “Reassessing the Marijuana Gateway Effect.” Addiction 97 (12):1493–1504.

Ogden, David W. 2009. “Memorandum for Selected United States Attorneys.”

Patrick, Stephen W., Carrie E. Fry, Timothy F. Jones, and Melinda B. Buntin. 2016. “Im- plementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates.” Health Affairs 35 (7):1324–1332.

Paulozzi, Leonard J., Edwin M. Kilbourne, and Hema A. Desai. 2011. “Prescription Drug Monitoring Programs and Death Rates from Drug Overdose.” Pain Medicine 12 (5):747– 754.

Pohl, R. Vincent. 2018. “Time Trends Matter: The Case of Medical Cannabis Laws and Opioid Overdose Mortality.” https://ssrn.com/abstract=3192703.

Powell, David, Rosalie Liccardo Pacula, and Mireille Jacobson. 2018. “Do Medical Mari- juana Laws Reduce Addictions and Deaths Related to Pain Killers?” Journal of Health Economics 58:29–42.

Rees, Daniel I., Joseph J. Sabia, Laura M. Argys, Joshua Latshaw, and Dhaval Dave. 2017. “With a Little Help from My Friends: The Effects of Naloxone Access and Good Samaritan Laws on Opioid-Related Deaths.” NBER Working Paper 23171.

Robins, Lee N., John E. Helzer, Michie Hesselbrock, and Eric Wish. 2010. “Vietnam Veterans Three Years after Vietnam: How Our Study Changed Our View of Heroin.” American Journal on Addictions 19 (3):203–211.

Ruhm, Christopher J. 2018. “Corrected US Opioid-Involved Drug Poisoning Deaths and Mortality Rates, 1999-2015: Corrected Opioid-Involved Mortality Rates.” Addiction 113 (7):1339–1344.

Smith, Rhet A. 2017. “The Effects of Medical Marijuana Dispensaries on Adverse Opioid Outcomes.” https://ssrn.com/abstract=3012381.

Van Gundy, Karen and Cesar J. Rebellon. 2010. “A Life-Course Perspective on the ”Gateway Hypothesis”.” Journal of Health and Social Behavior 51 (3):244–259.

Wen, Hefei and Jason M. Hockenberry. 2018. “Association of Medical and Adult-Use Mar- ijuana Laws With Opioid Prescribing for Medicaid Enrollees.” JAMA Internal Medicine 178 (5):673–679.